Online ISSN: 2187-2988 Print ISSN: 0911-1794
特定非営利活動法人日本小児循環器学会 Japanese Society of Pediatric Cardiology and Cardiac Surgery
Pediatric Cardiology and Cardiac Surgery 37(2): 73-77 (2021)


重症心不全に対する再生治療大阪大学から世界に発信する再生医療の実際The Regenerative Medicine for Heart Failure: From Transplant Therapy to In Vitro Study

大阪大学大学院医学系研究科 心臓血管外科学Department of Cardiovascular Surgery, Graduate School of Medicine, Osaka University ◇ Osaka, Japan

発行日:2021年8月1日Published: August 1, 2021


Heart transplantation, the most critical treatment method for severe heart failure, has an extremely serious shortage of donors. Although a new transplantation bill has been passed, it is expected to be difficult spread as a highly versatile treatment method in Western countries. On the other hand, for the left ventricular assist device (LVAD), since the waiting period for transplantation is long in Japan, complications such as infectious diseases and cerebral thrombosis greatly influence the results. To overcome this situation, expectations for regenerative medicine are increasing worldwide, and there is an urgent need to develop new treatments to replace heart transplantation and LVAD. Therefore, research on cell transplantation, tissue transplantation, and regenerative drug discovery using regenerative medicine methods to treat severe heart failure is progressing, as well as their clinical application. In this paper, along with the translational research of myoblast sheets, we will introduce heart failure treatment using iPS cell-derived cardiomyocyte sheets, introduce disease-specific iPS cells, and outline new heart failure treatment using regenerative medicine technology.

Key words: cell; heart failure; iPS cell; sheet

This page was created on 2021-06-21T09:01:25.026+09:00
This page was last modified on 2021-08-03T20:07:27.000+09:00